as 05-16-2025 4:00pm EST
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | TARRYTOWN |
Market Cap: | 4.1B | IPO Year: | 2005 |
Target Price: | $94.00 | AVG Volume (30 days): | 364.1K |
Analyst Decision: | Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 4.29 | EPS Growth: | 2.88 |
52 Week Low/High: | $62.35 - $90.04 | Next Earning Date: | 05-08-2025 |
Revenue: | $1,137,762,000 | Revenue Growth: | 1.10% |
Revenue Growth (this year): | 2.48% | Revenue Growth (next year): | 2.40% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Fritz Mary Beth | PBH | SVP Quality & Regulatory | Mar 10 '25 | Sell | $90.00 | 1,678 | $151,020.00 | 17,157 | |
Fritz Mary Beth | PBH | SVP Quality & Regulatory | Mar 3 '25 | Sell | $85.39 | 6,297 | $537,700.83 | 17,157 |
PBH Breaking Stock News: Dive into PBH Ticker-Specific Updates for Smart Investing
Morningstar Research
4 days ago
Argus Research
6 days ago
Simply Wall St.
9 days ago
GuruFocus.com
11 days ago
Morningstar Research
11 days ago
GlobeNewswire
12 days ago
GlobeNewswire
12 days ago
GuruFocus.com
12 days ago
The information presented on this page, "PBH Prestige Consumer Healthcare Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.